Tom Hale, chief executive officer of Oura Health Oy, wears an Oura Ring during an interview in San Francisco, California, US, on Friday, June 14, 2024.
David Paul Morris | Bloomberg | Getty Images
Biometric ring manufacturer Oura surprised Wall Street on Tuesday by postponing its initial public offering, citing “uncertainty” in market conditions despite claiming “strong demand” for its shares.
The delay reflects a broader acceleration in IPO postponements during 2026, extending beyond Oura’s company-specific challenges. Market conditions for new listings have suddenly become a significant headwind, driven largely by surging bond yields, according to analysts.
“The fact that we’ve had three or four in a row — a string of postponements — I think that does tell you something about the market,” Matthew Kennedy, senior strategist at Renaissance Capital, told CNBC. “You can’t really point to all four of them and say it’s company-specific issues.”
Four companies across different sectors, each seeking to raise at least $50 million, announced postponements or withdrew their IPOs entirely in the past week, according to Renaissance Capital data. That brings the third-quarter total to seven, up from four in the second quarter and three in the first.
Before Oura’s announcement Tuesday, nuclear power component maker Holtec Nuclear withdrew its IPO last Friday; materials company Amaero postponed its offering last Wednesday; and Bamboo Insurance delayed its IPO on Sept. 22.
“I’ve got a little bit of sympathy for market conditions as a rationale,” said Jay Ritter, director of the IPO Initiative at the University of Florida’s Warrington College of Business. “The fact that three prominent companies are doing this does indicate that it’s not company-specific.”
Solid IPO Year
Despite recent headwinds, 2026 has been a solid year for public offerings, with approximately $146.9 billion raised across 110 deals, excluding special purpose acquisition companies, according to Renaissance Capital. Those figures include mega offerings from SpaceX and South Korean memory maker SK Hynix in the second quarter.
Still, proceeds are down 30% from this time last year. In all of 2025, there were 202 IPOs — the most since 2021, when nearly 400 debuted. Total proceeds have surged 394% this year, largely due to the SpaceX, SK Hynix, and Cerebras offerings.
Health care and industrials are tied as the leading sectors for IPO launches year-to-date, each accounting for 24% of the total. Technology ranks third at 18%.
So far this year, 59% of all 2026 offerings are trading at or above their IPO price, although notably, SpaceX, SK Hynix, and Cerebras are all lagging.
Macroeconomic Headwinds
Recently, macroeconomic factors and concerns about the artificial intelligence buildout have weighed on the new-issue market.
“IPO activity came in below expectations in the third quarter of 2026, as more concerns about AI spending, a 19-year high in bond yields and resumed rate hikes weighed on the fall pickup,” Renaissance analysts wrote in a report to clients last week.
The Renaissance IPO ETF peaked in June this year when SpaceX launched.
Stock Chart IconStock chart icon
IPO year-to-date.
“AI-related stuff, including the build-out of the big infrastructure, still has a lot of enthusiasm for it. Things like data centers, there’s big demand there, but it’s largely a commodity business,” Ritter said.
Analysts noted that Oura, whose business is concentrated in its biometric ring product, likely faces its own distinct challenges.
“I would draw a line around Peloton, GoPro, FitBit and Oura. Investors have been burned pretty badly by narrow consumer products, and that is the reaction Oura is getting,” said Gil Luria, head of technology research at DA Davidson. “I don’t think it has to do with tech or tech allocation; I think it has to do with a narrow consumer product.”
Companies also have more alternatives than in the past to raise capital in private markets rather than public ones, according to lawyers specializing in public markets.
“The depth of private capital and alternatives is enormous now, and much more complex and diverse,” said Ian Schuman, chair of capital markets and public company representation practices at Latham & Watkins. “You don’t necessarily, absolutely need to tap the public markets if you’re not getting the value you want.”
